GlassScriptPhysician profile
Susan B Smith
NPI 1154441251
$8,414.76
in general payments reported to CMS, 2019-2025
25 companies · $2,145 in 2025
The $2,145 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,165 · 2022: $1,870 · 2023: $1,596 · 2024: $1,639 · 2025: $2,145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,722 · Education: $657.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,721.97 |
| Education | $657.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,295.71 | 2021-2025 | |
| Janssen Biotech, INC. | $1,014.16 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Pfizer INC. | $803.85 | 2021-2025 | |
| Amgen INC. | $741.17 | 2021-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $728.09 | 2021-2025 | Dupixent |
| Leo Pharma INC. | $433.76 | 2022-2025 | Adbry, Anzupgo |
| Ucb, INC. | $366.65 | 2021-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $360.75 | 2021-2025 | Ebglyss, Taltz, Olumiant |
| Genzyme Corporation | $282.56 | 2021-2025 | |
| Incyte Corporation | $246.50 | 2023-2025 | Opzelura |
| Sanofi-Aventis U.S. LLC | $184.99 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $146.18 | 2022-2025 | Sotyktu |
| Arcutis Biotherapeutics, INC. | $139.27 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $123.61 | 2021-2023 | |
| Gilead Sciences, INC. | $122.26 | 2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $120.45 | 2021-2024 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $55.76 | 2023-2024 | Vtama |
| Lnhc, INC | $47.64 | 2025 | Zelsuvmi |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $47.48 | 2021-2025 | Jublia, Cabtreo, Arazlo |
| Sun Pharmaceutical Industries INC. | $40.28 | 2022-2025 | |
| Organon LLC | $35.31 | 2025 | Vtama |
| Botanix Sb INC | $27.62 | 2025 | Sofdra |
| Abbott Laboratories | $20.66 | 2022 | |
| Bard Peripheral Vascular, INC. | $16.88 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.17 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.